Clinical recommendations for diagnosing, treatment and monitoring of patients with uterine cervical cancer-croatian oncology society and croatian society for gynecology and obstetrics as croatian medical association units and croatian society of gynecological oncology;Klinlčke upute za dijagnostiku, lijek̂enje i praćenje bolesnica oboljelih od raka vrata maternice hrvatskoga onkoloskog društva i hrvatskog društva za ginekologiju i opstetriciju hrvatskoga lijecničkog zbora te hrvatskoga ginekološkoonkoloskog društva

Lijecnicki Vjesnik

Volumn 135, Issue 9-10, 2013, Pages 225-229

  Vrdoljak, Eduard ^a   Haller, Herman ^b   Corušić, Ante ^c   Jelavić, Tihana Boraska ^a   Matković, Višnja ^c   Strinić, Tomislav ^a   Karnjuš Begonja, Ružica ^b   Barišić, Dubravko ^c   Tomić, Snježana ^a   Babić, Damir ^c   Kukura, Vlastimir ^d   Miše, Branka Petric ^a   Padovan, Ranka Stern ^c   Matic, Mate ^e   Puljiz, Mario ^f   Krasevic, Maja ^a   Fröbe, Ana ^f   Topolovec, Zlatko ^e   Hajredini, Adem ^c   Vrdoljak Mozetlc, Danijela ^a   Mamula, Ozren ^a   Bolanča, Ines Krivak ^d   Brnčić Fischer, Alemka ^b   more..

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b KBC RIJEKA   (Croatia)

^c KBC Zagreb   (Croatia)

^d Klinifka Bol Nica Merkur   (Croatia)

^e JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

^f SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CROATIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMAN; HYSTERECTOMY; LYMPH NODE DISSECTION; OVARIECTOMY; PATHOLOGY; PRACTICE GUIDELINE; SALPINGECTOMY; UTERINE CERVICAL NEOPLASMS;

CROATIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; LYMPH NODE EXCISION; NEOPLASM STAGING; OVARIECTOMY; SALPINGECTOMY; UTERINE CERVICAL NEOPLASMS;

EID: 84888309075     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Incidencija raka u Hrvatskoj 2010. Bilten br. 35. Zagreb: Hrvatski za-vod za javno zdravstvo; 2012.
2. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs (WHO Classification of Tumours). Lyon: IARC Press; 2003, str. 260.
3. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynecol Obstetr 2009; 105: 103-4.
4. Moore DH. Surgical Staging and Cervical Cancer: after 30 years, have we reached a conclusion? Cancer 2008; 112: 1874-6.
5. Malier H, Kraševicć M., Mamuia O, Brnčić- Fischer A, Eminović S, Manestar M. Treatment and outcome of stage Ia1 squamous cell carcinoma of the uterine cervix. Int J Gynaecol Obstetr 2011; 113(1): 72-5.
6. Sevin BU, Nadji M. Averette HE i sur. Microinvasive carcinoma of the cervix. Cancer 1992; 70(8): 2121-8.
7. Gadducci A, Sartori E, Maggino T i sur. The clinical outcome of patients with stage Ia1 and Ia2 squamous cell carcinoma of the uterine cervix: a Cooperation Task Force (CTF) study. Eur J Gynaecol Oncol 2003; 24(6): 513-6.
8. Perez CA, Kavanagh BD. Uterine cervix. U: Perez CA, Brady LW, Hal-perin EC, Schmidt-Ullrich R, ur. Principles and Practice of Radiation Oncology. 4.izd. Philadelphia: Lippincott Williams and Wilkins: 2004, str. 1843.
9. Koliopoulos G, Soliriadis A, Kyrigou M, Martin-Hirsch P, Makydimas G, Paraskevadis E. Conservative surgical methods for FIGO stage IA2 squamous cervical carcinoma and their role in preserving women's fertility. Gynecol Oncol 2004; 93(2): 469-73.
10. Peters WA, Liu PY, Barret RJ 2nd i sur. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18(8): 1606-13.
11. Landoni F, Maneo A, Colombo A i sur. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350: 535-10.
12. Diaz JP, Sonoda Y, Leitao MM i sur. Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecol Oncol 2008; 111: 255-60.
13. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 1999; 73(2): 177-83.
14. Rotman M, Sedlis A, Piedmonte MR i sur. A phase III randomised trial of postoperative pelvic irradiation in stage IB cervical cancer with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006; 65(1): 169-76.
15. Whitney CW, Sause W, Bundy BN i sur. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative paraaortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17(5): 1339-48.
16. Morris M, Eifel PJ. Lu Jisur. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340(15): 1137-43.
17. Rose PG, Bundy BN, Watkins EB i sur. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340(15): 1144-53.
18. Keys HM, Bundy BN, Stehman FB i sur. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340(15): 1154-61.
19. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemora-diotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database of Systematic Reviews 2010, Issue 1. art. No.: CD008285. DOI: 10.1002/14651858. CD008285.
20. Viani GA, Manta GB, Stefano EJ, de Fendi LI. Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy - a metaanalysis of clinical trials. J Exp Clin Cancer Res 2009; 28: 47.
21. Gonzales Duenas A, Zarba JJ, Alcedo JC i sur. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011; 29(13): 1678-85.
22. Wong LC, Ngan HYS, Cheung ANY, Cheng DKL, Ng Y, Choy DTK. Chemoradiation and Adjuvant Chemotherapy in Cervical Cancer. J Clin Oncol 1999; 17(7): 2055.
23. Vrdoljak E, Omrčen T, Saratlija-Novaković Z i sur. Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix - Final results of a prospective phase-II study. Gynecol Oncol 2006; 103: 494-9.
24. Girinsky T, Key A, Roche B i sur. Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993; 27: 1051-56.
25. Neoadjuvant chemotherapy for cervical cancer meta-analysis collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 2003; 39: 2470-86.
26. Eddy GL, Bundy BN, Creasman WT i sur. Treatment of («bulky») stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol 2007; 106: 362-9.
27. Tzioras S, Pavlidis N, Paraskevaidis E, Ioannidis JPA. Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis. Cancer Treat Rev 2007; 33: 24-38.
28. Thigpen T, Shingleton H, Homesley H, Laggasse L, Blessing J. Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix. Cancer 1981; 48: 899-903.
29. Moore DH, Blessing JA, McQuellon RP i sur. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2004; 22 (15): 3113-9.
30. Weiss GR, Green S, Hannigan EV i sur. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol 1990; 39(3): 332-6.
31. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14(3): 792-5.
32. Coleman RE, Harper PG, Gallagher C i sur. A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 1986; 18(3): 280-3.
33. Sutton GP, Blessing JA, McGuire WP, Patton T, Look KY. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstetr Gynecol 1993; 168: 805-7.
34. Long HJ, Bundy BN, Grendys EC i sur. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005; 23: 4617-25.
35. Monk BJ, Sill MW, McMeekin DS i sur. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecological Oncology Group study. J Clin Oncol 2009; 27: 4649-55.
36. Omura GA, Blessing JA, Vaccarello L i sur. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997; 15: 16.
37. Preuzeto sa: www.nccn.org. NCCN Clinical Practice Guidelines in Oncology. Cervical Cancer. V 1.2013.
38. Gadducci A, Tana R, Cosio S, Cionini L. Treatment options in recurrent cervical cancer. Oncology Lett 2010; 1: 3-11.
39. Elit L, Fyles AW, Devries MC, Oliver TK, Fung-Kee-Fung M. The Gynecology Cancer Disease Site Group. Follow-up for women after treatment for cervical cancer: A systematic review. Gynecol Oncol 2009; 114: 528-35.